KURA.NASDAQKura Oncology, INC

Form 4: Kura Oncology CSO Sells Shares for Tax Cover

Sentiment:

Insider Transaction Report

📋All filings for Kura Oncology, INC
🔒Login to Follow

Kura Oncology's Chief Scientific Officer, Francis Burrows, sold 1,311 shares of common stock at $8.4607 per share to cover tax obligations related to RSU vesting.

Summary

  • Francis Burrows, Chief Scientific Officer of Kura Oncology, Inc. (KURA), reported a transaction involving the company's common stock.
  • The transaction, dated January 27, 2026, involved the disposition of 1,311 shares of common stock.
  • The shares were sold at a price of $8.4607 per share.
  • The sale was a 'sell-to-cover' transaction, executed to satisfy tax obligations associated with the vesting of Restricted Stock Units (RSUs) received by Mr. Burrows on January 26, 2022.
  • Following this transaction, Mr. Burrows beneficially owns 32,424 shares of Kura Oncology common stock directly.
  • The transaction was made pursuant to a Rule 10b5-1(c) pre-arranged trading plan.

Sentiment

Score: 5

Explanation: Neutral. The transaction is a routine sell-to-cover for tax purposes, not indicative of a change in sentiment towards the company's prospects or operational performance.

Future Outlook

NA

Industry Context

This is a routine insider transaction for tax purposes and does not provide specific insights into broader industry trends or competitive positioning.

Stakeholder Impact

  • Minimal direct impact on shareholders as this is a routine tax-related transaction by an insider.
  • Positive for the reporting person (Francis Burrows) as it addresses tax liabilities arising from RSU vesting.

Key Dates

DateDescription
01/26/2022Date RSU was received by the Reporting Person.
01/27/2026Transaction date for the sale of common stock.

Recommendation

hold

The filing details a routine 'sell-to-cover' transaction by an executive to satisfy tax obligations from RSU vesting. This type of transaction is common and typically does not reflect a change in the executive's outlook on the company's fundamentals or future prospects. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Kura Oncology, KURA, Francis Burrows, Insider Trading, Form 4, Stock Sale, RSU Vesting, Sell-to-Cover, Biotechnology, Pharmaceuticals

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.